• Lexaria outlined accelerating demand for oral GLP-1 drugs, citing a $62.8 billion 2025 market forecast to reach $254.2 billion by 2034.
• Grandview Research data cited: injectables held 93% share in 2025; oral GLP-1 products remain about 5% to 7%.
• Using a $73.4 billion 2026 market estimate, Lexaria pegged today’s oral GLP-1 opportunity at about $5.1 billion.
• At 35% oral penetration on a $254.2 billion 2034 market, the oral segment would reach about $89 billion.
• Lexaria positioned DehydraTECH as an oral absorption enhancer under evaluation for GLP-1s, aimed at improving uptake, lowering side effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610060910ACCESSWRNAPR_____1233250) on October 06, 2026, and is solely responsible for the information contained therein.